V451 vaccine

V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology,[1] and the MF59 adjuvant.[2]

V451 vaccine
Vaccine description
Target diseaseCOVID-19
TypeSubunit
Clinical data
Other namesSARS-CoV-2 Sclamp
Routes of
administration		Intramuscular
Legal status
Legal status
  • Terminated
Part of a series on the
COVID-19 pandemic
Timeline
2019

2020

2021
Locations
  • By continent
  • By conveyance
International response
Medical response
Impact
  • Socio-economic
  • By industry
 COVID-19 Portal

Termination of development

The development of the vaccine was cancelled on 11 December 2020 after false-positive tests for HIV antibodies in a number of participants in the Phase I trial of the vaccine.[3][4] As part of the vaccine's design, researchers added "a fragment of one protein found on the HIV virus"[5] as a "ground-breaking molecular clamp technology"[6] which led to "a partial antibody response" to HIV and would have interfered with HIV screening tests.[7]

Nine days prior to the termination, on 2 December, the first emergency use authorisation was granted to a COVID-19 vaccine; the Pfizer–BioNTech COVID-19 vaccine in the United Kingdom.[8] Following the termination of V451, vaccine production capacity by CSL Limited was diverted to the Oxford–AstraZeneca COVID-19 vaccine.[9]

See also

References
  1. "UQ-CSL V451 Vaccine". www.precisionvaccinations.com. Retrieved 2020-12-11.
  2. Meneguzzi J (13 November 2020). "Why a COVID-19 vaccine could further imperil deep-sea sharks". National Geographic.
  3. "Covid: Australian vaccine abandoned over false HIV response". BBC News. 2020-12-11. Retrieved 2020-12-11.
  4. Reuters Staff (2020-12-10). "BRIEF-CSL Says Will Not Progress UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials". Reuters. Retrieved 2020-12-11.
  5. Slezak, Michael (11 December 2020). "How the UQ coronavirus vaccine induced false-positive HIV test results and why scientists were prepared". ABC News.
  6. Smyth J (11 December 2020). "Australia abandons local Covid vaccine over HIV test concerns". Financial Times.(subscription required)
  7. "Australia ends local COVID vaccine trials due to HIV false positives". Deutsche Welle. 11 December 2020.
  8. "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 2 December 2020. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
  9. "COVID-19 Update". www.csl.com. Retrieved 2021-01-31.
  • Clinical trial number NCT04495933 for "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.